obesity

News

Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.

News

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

News

Hims & Hers has launched its direct-to-consumer weight-loss therapy channel in the UK, offering Wegovy, Mounjaro, and OTC option Orlos.

R&D

In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.

Digital

AI-powered integrated platforms offer an elemental shift in the way that clinical trials are conducted.

News

A real-world study exploring the long-term effects of Eli Lilly's weight-loss therapy tirzepatide in primary care settings has started in the UK.